Drug Patents owned by Allergan Holdings

1. List of Viberzi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8609709 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US7786158 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US10213415 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US9115091 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(5 years from now)

US8691860 ALLERGAN HOLDINGS Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(5 years from now)

US7741356 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8344011 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US9700542 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US9205076 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US8772325 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US9364489 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(5 years from now)

US9789125 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(5 years from now)

US11229627 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

US11007179 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

US10188632 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

US9675587 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

US11160792 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

US11311516 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

US11090291 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

US11484527 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(10 years from now)

Drugs and Companies using ELUXADOLINE ingredient

Market Authorisation Date: 27 May, 2015

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food; Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)

Dosage: TABLET;ORAL

How can I launch a generic of VIBERZI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in